Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL28124710 | 0.84 | AKR1C3 (0.69) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL27599210 | 0.84 | PTGS2 (0.61) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL27617619 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| Indomethacin SCHEMBL5492772 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| Oxametacin SCHEMBL29378857 | 0.79 | PTGS1 (1.00) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| Oxametacin SCHEMBL24552 | 0.79 | PTGS1 (1.00) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL14405006 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| Betadex SCHEMBL11491489 | 0.79 | AKR1C3 (0.71) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| Betadex SCHEMBL30950731 | 0.79 | AKR1C3 (0.71) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL9657228 | 0.79 | PTGS1 (0.85) | PTGS2PTGS1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3074 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-4034087-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS Research Inc. (CA) | 2022-08-03 | — | — | EP | claimed |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2022-07-14 | — | — | US | claimed |
| US-20210145763-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | EYE CO PTY LTD. (AU) | 2021-05-20 | — | — | US | claimed |
| WO-2021056106-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2021-04-01 | — | — | WO | claimed |
| EP-3773651-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | Eye Co Pty Ltd. (AU) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191800-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | EYE CO PTY LTD (AU) | 2019-10-10 | — | — | WO | claimed |
| US-20180111944-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2018-04-26 | — | — | US | claimed |
| US-9814712-B2 | (S)-pirlindole and its pharmaceutically acceptable salts for use in medicine | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2017-11-14 | — | — | US | claimed |
| EP-3057589-B1 | (S)-PIRLINDOLE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL S A (PT) | 2017-08-02 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0249561-B1 | COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE LIPOSOME COMPANY, INC. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1987007506-A1 | METHODS AND COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE LIPOSOME COMPANY, INC. (US) | 1987-12-17 | — | — | WO | claimed |
| EP-0249561-A2 | Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs | THE LIPOSOME COMPANY, INC. (US) | 1987-12-16 | — | — | EP | claimed |